RetinaLyze System
RetinaLyze System develops AI-assisted ophthalmic screening software for eye-care providers, covering glaucoma, diabetic retinopathy, cataract, AMD, and ROP. Founded in 2013 in Hellerup, Denmark, the bootstrapped company serves healthcare professionals via a cloud platform with API integration.
- Company typePrivate
- Founded2013
- HeadquartersHellerup, Denmark
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What RetinaLyze System does
RetinaLyze System develops AI-assisted ophthalmic screening software designed to detect eye diseases from retinal imagery. The company's product screens for five clinical conditions — glaucoma, diabetic retinopathy, cataract, age-related macular degeneration (AMD), and retinopathy of prematurity (ROP) — positioning it as a multi-condition screening platform rather than a single-disease algorithm. The software is delivered to eye-care professionals, opticians, and general practitioners, and is exposed via an application programming interface (API) for integration into third-party clinical workflows and electronic health record systems, indicating a platform rather than purely standalone-portal distribution model.
The company was founded in 2013 and is headquartered in Hellerup, Denmark. Leadership comprises founder and CEO Barbara Anthonsen, co-founder and CCO Ganesh Ram, and co-founder, CTO and Technical Manager Morten Guldager Moller. Headcount is reported in the 11–50 range, placing it in the small-SMB category. The company operates as a private entity and, per available records, has not raised external venture funding — its documented funding history shows a 2014 round with $0 raised, consistent with a bootstrapped capital structure.
The business model centers on selling or licensing AI screening software to healthcare professionals and clinics, though pricing structure (per-scan fee, subscription, or capital license) is not publicly disclosed. No named customer accounts, distribution partnerships, or revenue figures are available in the input, limiting visibility into commercial traction. Geographic reach beyond Denmark is not documented, and the company competes in a healthcare AI segment that includes better-capitalized entrants with disclosed regulatory clearances, making capital-light bootstrapping a notable strategic constraint.
RetinaLyze System firmographics
Firmographics- Name
- RetinaLyze System
- Website
- https://retinalyze.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- RetinaLyze System develops AI-assisted ophthalmic screening software for eye-care providers, covering glaucoma, diabetic retinopathy, cataract, AMD, and ROP. Founded in 2013 in Hellerup, Denmark, the bootstrapped company serves healthcare professionals via a cloud platform with API integration.
- Ownership category
- akta.pro rank
RetinaLyze System industry classification
Industry- Product category
- AI Ophthalmology Diagnostics
- NAICS
- Custom Computer Programming Services (541511)
- SIC
- Optical Instruments & Lenses (3827), Services-Computer Programming Services (7371)
- akta.pro primary industry
- Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography) (HLAHAJAB)
- akta.pro secondary industries
- Ocular Imaging & Diagnostic Testing Centers (HLAKAKAN), Retina & Vitreous Specialists (HLAKAKAE)
Keywords
Where RetinaLyze System is headquartered
LocationHeadquarters
- HQ city
- Hellerup
- HQ country
- Denmark
- HQ region
- Europe
Markets served
RetinaLyze System business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations
RetinaLyze System product offering
Product offeringCore offering
RetinaLyze System develops artificial intelligence-powered software that screens eyes for ophthalmic diseases including glaucoma, diabetic retinopathy, cataract, age-related macular degeneration (AMD), and retinopathy of prematurity (ROP). The software provides AI-assisted diagnostic support to eye care providers and healthcare professionals for early detection of these conditions.
Differentiator
Problem solved
Functional benefit
Products and services
- RetinaLyze AI Ophthalmic Screening Software AI-assisted diagnostic software that screens retinal images for eye diseases including glaucoma, diabetic retinopathy, cataract, age-related macular degeneration (AMD), and retinopathy of prematurity (ROP). Built for eye care providers and healthcare professionals who need automated early detection support.
Companies that use RetinaLyze System
Customer profileSegments1 record
Ideal customer profiles1 record
RetinaLyze System technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
RetinaLyze System partnerships and signals
Strategic signalRecent moves2 records
Expansion highlights2 records
RetinaLyze System competitors and assessment
Company assessmentDirect peers
- Digital Diagnostics: Pioneer in autonomous AI diagnostics for diabetic retinopathy (IDx-DR), the first FDA-cleared AI diagnostic in any specialty. Directly comparable to RetinaLyze's DR screening use case and software-based delivery model.
- iCare (Revenio Group): Provides ophthalmic diagnostic devices including retinal imaging and glaucoma screening tools. Overlaps with RetinaLyze's target conditions and serves optometrists/ophthalmologists.
- AEYE Health: AI retinal screening provider with FDA clearance for DR detection from fundus images. Closely aligned product offering to RetinaLyze's ophthalmic AI screening positioning.
- Optomed: Finnish company offering handheld fundus cameras plus AI-based screening software for DR and other retinal diseases. Comparable combination of imaging device plus AI diagnostics for eye care providers.
- Eyenuk: Developer of EyeArt, an FDA-cleared AI system for autonomous DR screening. Operates in the same AI retinal screening category with similar eye care provider customer base.
Broad incumbents
- Topcon Healthcare: Major ophthalmic device manufacturer offering fundus cameras, OCT, and integrated AI screening software. A broad incumbent that competes with RetinaLyze at the integrated imaging-plus-AI layer.
- ZEISS Medical Technology: Global ophthalmic equipment leader offering retinal imaging, OCT, and AI-assisted diagnostics. Sets the standard for clinical ophthalmic workflows where AI software like RetinaLyze must integrate.
Emerging players
- Thirona Retina: AI image analysis provider with ophthalmic screening products including retinal image analysis. Emerging competitor with European base similar to RetinaLyze, focusing on AI-driven diagnostics.
- OrCam Technologies: AI-driven vision assistance technology company. While its primary product is wearable low-vision assistance, it represents a broader AI-vision thematic peer relevant to RetinaLyze's category.
Regional players
- HEINE Optotechnik: German-headquartered manufacturer of ophthalmic diagnostic instruments including direct and indirect ophthalmoscopes. Comparable in serving European eye care professionals with diagnostic tools, though primarily hardware-focused.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
RetinaLyze System social profiles
Digital presenceRetinaLyze System financial estimates
Financial estimateRevenue estimate
Valuation estimate
RetinaLyze System leadership team
Management profileNumber of profiles
Profiles3 records
RetinaLyze System funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
RetinaLyze System M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about RetinaLyze System
What does RetinaLyze System do?
RetinaLyze System develops artificial intelligence-powered software that screens eyes for ophthalmic diseases including glaucoma, diabetic retinopathy, cataract, age-related macular degeneration (AMD), and retinopathy of prematurity (ROP). The software provides AI-assisted diagnostic support to eye care providers and healthcare professionals for early detection of these conditions.
Is RetinaLyze System a public or private company?
RetinaLyze System is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was RetinaLyze System founded?
RetinaLyze System was founded in 2013. It employs 11 to 50 people.
Where is RetinaLyze System based?
RetinaLyze System is headquartered in Hellerup, Denmark, in the Europe region.
Who are RetinaLyze System's main competitors?
Direct peers on record are Digital Diagnostics, iCare (Revenio Group), AEYE Health, Optomed and Eyenuk. Broad incumbents are Topcon Healthcare and ZEISS Medical Technology. Emerging players are Thirona Retina and OrCam Technologies. HEINE Optotechnik is listed as a regional player.
Does RetinaLyze System have an API?
No public API is recorded for RetinaLyze System.
What industry is RetinaLyze System in?
RetinaLyze System's product category is AI Ophthalmology Diagnostics. Its primary akta.pro industry code is HLAHAJAB, Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography), with a secondary code of HLAKAKAN, Ocular Imaging & Diagnostic Testing Centers. Its NAICS code is 541511 and its SIC code is 3827.